患者特定的深度线下人工胰腺用于1型糖尿病患者的血糖调节
Yixiang Deng1, Kevin Arao2, Christos S Mantzoros2,3
1Department of Computer and Information Sciences, University of Delaware, Newark, DE 19716, USA.
Smart health (Amsterdam, Netherlands)
|March 2, 2026
概括
这项研究使用人工智能开发了一种人工胰腺,用于自动化1型糖尿病 (T1DM) 患者的胰岛素剂量. 与标准的人工胰腺系统相比,该系统可以考虑运动,改善血糖控制和安全性.
科学领域:
- 生物医学工程 生物医学工程
- 计算生物学 计算生物学
- 人工智能在医学中的应用
背景情况:
- 1型糖尿病 (T1DM) 的管理包括平衡胰岛素输送,以防止危险的低血糖和慢性高血糖.
- 目前的人工胰腺系统难以解释身体活动,可能导致活跃患者过量服用胰岛素和低血糖.
- 精确的葡萄糖监测和个性化的胰岛素剂量对于缓解T1DM并发症至关重要.
研究的目的:
- 开发一个先进的人工胰腺框架,整合系统生物学信息的神经网络 (SBINN) 和深度强化学习 (RL) 以用于T1DM的自动胰岛素剂量.
- 创建特定于患者的计算模型,捕捉葡萄糖-胰岛素动态,考虑碳水化合物摄入量和体育炼强度.
- 提高T1DM患者的葡萄糖水平安全性和提高胰岛素剂量准确性,特别是那些身体活跃的人.
主要方法:
- 开发一个结合SBINN用于患者特定建模和深度RL用于自动注射胰岛素的计算框架.
- 利用可穿戴设备的T1DM患者数据来训练和验证SBINN模型.
- 实施和评估两个深度RL算法,以基于个性化的葡萄糖-胰岛素动态优化胰岛素输送.
主要成果:
- 针对患者的特定计算模型准确地模拟了葡萄糖-胰岛素动态,并结合了个人的碳水化合物摄入量和运动水平.
- 开发的针对患者的人工胰腺,由深度RL提供动力,证明了卓越的胰岛素剂量控制.
- 与基线数据相比,该系统导致T1DM患者的葡萄糖水平更安全.
结论:
- 整合SBINN和深度RL为T1DM管理中的个性化人工胰腺系统提供了一个有希望的方法.
- 考虑身体活动和个体代谢反应对于下一代人工胰腺设计至关重要.
- 这种人工智能驱动的框架有可能显著改善血糖控制,并减少T1DM患者的并发症.
更多相关视频
相关概念视频
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.8K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.8K
Diabetes Mellitus: Overview and Type I Subtype
5.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K
Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Diabetes Mellitus: Type 2 and Gestational
5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K


